Inhibrx Biosciences, Inc. INBX Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept inbx:InterestIncomeNonoperating.
The official record: Inhibrx Biosciences, Inc.’s 10-K, filed March 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Inhibrx Biosciences, Inc.'s interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Inhibrx Biosciences, Inc.'s interest income?
- Inhibrx Biosciences, Inc. (INBX) reported interest income of $1.89M in Q4 2025.
- How has Inhibrx Biosciences, Inc.'s interest income changed year-over-year?
- Inhibrx Biosciences, Inc.'s interest income decreased by 31.0% year-over-year, from $2.74M to $1.89M.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s interest income?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s interest income has grown at a -20.4% compound annual growth rate (CAGR), from $11.92M to $7.55M.
- What does interest income mean?
- This metric captures the income generated from cash, cash equivalents, and short-term investment holdings held by the company. It serves as a measure of the yield earned on the company's liquidity position while awaiting deployment into clinical development programs. For a clinical-stage biopharmaceutical company, this reflects the efficiency of treasury management and the preservation of capital.